Cialis

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
20-09-2023
Produktens egenskaper Produktens egenskaper (SPC)
20-09-2023

Aktiva substanser:

tadalafil

Tillgänglig från:

Eli Lilly Nederland B.V.

ATC-kod:

G04BE08

INN (International namn):

tadalafil

Terapeutisk grupp:

Urologicals

Terapiområde:

Erectile Dysfunction

Terapeutiska indikationer:

Treatment of erectile dysfunction.In order for tadalafil to be effective, sexual stimulation is required.Cialis is not indicated for use by women.

Produktsammanfattning:

Revision: 32

Bemyndigande status:

Authorised

Tillstånd datum:

2002-11-12

Bipacksedel

                                61
B. PACKAGE LEAFLET
62
PACKAGE LEAFLET: INFORMATION FOR THE USER
CIALIS 2.5 MG FILM-COATED TABLETS
tadalafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What CIALIS is and what it is used for
2.
What you need to know before you take CIALIS
3.
How to take CIALIS
4.
Possible side effects
5
How to store CIALIS
6.
Contents of the pack and other information
1.
WHAT CIALIS IS AND WHAT IT IS USED FOR
CIALIS is a treatment for adult men with erectile dysfunction. This is
when a man cannot get, or keep
a hard, erect penis suitable for sexual activity. CIALIS has been
shown to significantly improve the
ability of obtaining a hard erect penis suitable for sexual activity.
CIALIS contains the active substance tadalafil which belongs to a
group of medicines called
phosphodiesterase type 5 inhibitors. Following sexual stimulation
CIALIS works by helping the blood
vessels in your penis to relax, allowing the flow of blood into your
penis. The result of this is
improved erectile function. CIALIS will not help you if you do not
have erectile dysfunction.
It is important to note that CIALIS does not work if there is no
sexual stimulation. You and your
partner will need to engage in foreplay, just as you would if you were
not taking a medicine for
erectile dysfunction.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE CIALIS
DO NOT TAKE CIALIS IF YOU:
-
are allergic to tadalafil or any of the other ingredients of this
medicine (listed in section 6).
-
are taking any form of organic nitrate or nitric oxide donors such as

                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
CIALIS 2.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each tablet contains 2.5 mg tadalafil.
Excipient with known effect
_ _
Each coated tablet contains 87 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Light orange-yellow and almond shaped tablets, marked "C 2 ½" on one
side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of erectile dysfunction in adult males.
In order for tadalafil to be effective, sexual stimulation is
required.
CIALIS is not indicated for use by women.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adult men _
In general, the recommended dose is 10 mg taken prior to anticipated
sexual activity and with or
without food.
In those patients in whom tadalafil 10 mg does not produce an adequate
effect, 20 mg might be tried. It
may be taken at least 30 minutes prior to sexual activity.
The maximum dose frequency is once per day.
Tadalafil 10 and 20 mg is intended for use prior to anticipated sexual
activity and it is not
recommended for continuous daily use.
In patients who anticipate a frequent use of CIALIS (i.e., at least
twice weekly) a once daily regimen
with the lowest doses of CIALIS might be considered suitable, based on
patient choice and the
physician’s judgement.
In these patients the recommended dose is 5 mg taken once a day at
approximately the same time of
day. The dose may be decreased to 2.5 mg once a day based on
individual tolerability.
The appropriateness of continued use of the daily regimen should be
reassessed periodically.
3
Special populations
_Elderly men _
Dose adjustments are not required in elderly patients.
_Men with renal impairment _
Dose adjustments are not required in patients with mild to moderate
renal impairment. For patients
with severe renal impairment 10 mg is the maximum recommended dose.
Once-a-day dosing of
tadalafil is not recommended in pati
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 20-09-2023
Produktens egenskaper Produktens egenskaper bulgariska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 24-09-2015
Bipacksedel Bipacksedel spanska 20-09-2023
Produktens egenskaper Produktens egenskaper spanska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 24-09-2015
Bipacksedel Bipacksedel tjeckiska 20-09-2023
Produktens egenskaper Produktens egenskaper tjeckiska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 24-09-2015
Bipacksedel Bipacksedel danska 20-09-2023
Produktens egenskaper Produktens egenskaper danska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 24-09-2015
Bipacksedel Bipacksedel tyska 20-09-2023
Produktens egenskaper Produktens egenskaper tyska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 24-09-2015
Bipacksedel Bipacksedel estniska 20-09-2023
Produktens egenskaper Produktens egenskaper estniska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 24-09-2015
Bipacksedel Bipacksedel grekiska 20-09-2023
Produktens egenskaper Produktens egenskaper grekiska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 24-09-2015
Bipacksedel Bipacksedel franska 20-09-2023
Produktens egenskaper Produktens egenskaper franska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 24-09-2015
Bipacksedel Bipacksedel italienska 20-09-2023
Produktens egenskaper Produktens egenskaper italienska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 24-09-2015
Bipacksedel Bipacksedel lettiska 20-09-2023
Produktens egenskaper Produktens egenskaper lettiska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 24-09-2015
Bipacksedel Bipacksedel litauiska 20-09-2023
Produktens egenskaper Produktens egenskaper litauiska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 24-09-2015
Bipacksedel Bipacksedel ungerska 20-09-2023
Produktens egenskaper Produktens egenskaper ungerska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 24-09-2015
Bipacksedel Bipacksedel maltesiska 20-09-2023
Produktens egenskaper Produktens egenskaper maltesiska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 24-09-2015
Bipacksedel Bipacksedel nederländska 20-09-2023
Produktens egenskaper Produktens egenskaper nederländska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 24-09-2015
Bipacksedel Bipacksedel polska 20-09-2023
Produktens egenskaper Produktens egenskaper polska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 24-09-2015
Bipacksedel Bipacksedel portugisiska 20-09-2023
Produktens egenskaper Produktens egenskaper portugisiska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 24-09-2015
Bipacksedel Bipacksedel rumänska 20-09-2023
Produktens egenskaper Produktens egenskaper rumänska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 24-09-2015
Bipacksedel Bipacksedel slovakiska 20-09-2023
Produktens egenskaper Produktens egenskaper slovakiska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 24-09-2015
Bipacksedel Bipacksedel slovenska 20-09-2023
Produktens egenskaper Produktens egenskaper slovenska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 24-09-2015
Bipacksedel Bipacksedel finska 20-09-2023
Produktens egenskaper Produktens egenskaper finska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 24-09-2015
Bipacksedel Bipacksedel svenska 20-09-2023
Produktens egenskaper Produktens egenskaper svenska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 24-09-2015
Bipacksedel Bipacksedel norska 20-09-2023
Produktens egenskaper Produktens egenskaper norska 20-09-2023
Bipacksedel Bipacksedel isländska 20-09-2023
Produktens egenskaper Produktens egenskaper isländska 20-09-2023
Bipacksedel Bipacksedel kroatiska 20-09-2023
Produktens egenskaper Produktens egenskaper kroatiska 20-09-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 24-09-2015

Sök varningar relaterade till denna produkt

Visa dokumenthistorik